Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congress

NEXT STORY
MPI’s CEO exercises warrants – increase of share capital in the company
PREV STORY
Shire plc : Statement re Proposal from Takeda Pharmaceutical Company Limited
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FibroGen Reports Fiscal 2016 Financial Results

SAN FRANCISCO, March 01, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical ...

author_avatar
NASDAQ Market News

CytomX Therapeutics Presents Clinical Data from Probody™ Platform and CX-072 at 2018 ESMO Annual Meeting

- Additional Data Supports PD-L1 Targeting Probody CX-072 as Well Tolerated with Antitumor Activity ...

author_avatar
NASDAQ Market News

Loxo Oncology to Present at the Cowen and Company 38th Annual Health Care Conference

STAMFORD, Conn., March 06, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical ...

author_avatar
NASDAQ Market News